SORACE, CHIARA
 Distribuzione geografica
Continente #
NA - Nord America 172
AS - Asia 104
EU - Europa 69
Continente sconosciuto - Info sul continente non disponibili 17
SA - Sud America 6
AF - Africa 2
Totale 370
Nazione #
US - Stati Uniti d'America 166
SG - Singapore 42
IT - Italia 29
CN - Cina 24
HK - Hong Kong 10
RU - Federazione Russa 8
BD - Bangladesh 7
DE - Germania 6
NL - Olanda 6
FR - Francia 5
IN - India 5
SE - Svezia 5
BR - Brasile 4
CA - Canada 4
GB - Regno Unito 4
JP - Giappone 4
VN - Vietnam 4
AT - Austria 3
ID - Indonesia 2
PH - Filippine 2
CL - Cile 1
CO - Colombia 1
EG - Egitto 1
ES - Italia 1
FI - Finlandia 1
HN - Honduras 1
IR - Iran 1
JO - Giordania 1
LV - Lettonia 1
NI - Nicaragua 1
PK - Pakistan 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 353
Città #
San Jose 26
Singapore 25
Ashburn 17
Hong Kong 10
North Charleston 10
Beijing 8
Los Angeles 8
Council Bluffs 7
Rome 6
New York 5
Tokyo 4
Chandigarh 3
Chicago 3
Las Vegas 3
Toronto 3
Astoria 2
Atlanta 2
Berlin 2
Brooklyn 2
Buffalo 2
Dallas 2
Ho Chi Minh City 2
Louisville 2
Milan 2
Santa Clara 2
São Paulo 2
Xi'an 2
Agropoli 1
Alexandria 1
Amman 1
Amsterdam 1
Baltimore 1
Bastos 1
Brazil 1
Bridgeport 1
Cairo 1
Cerritos 1
Charlotte 1
Chengdu 1
City of London 1
Columbus 1
Denver 1
Detroit 1
Elk Grove 1
Elk Grove Village 1
Flint 1
Frankfurt am Main 1
Genoa 1
Grand Rapids 1
Itatiba 1
Jakarta 1
Johannesburg 1
Karachi 1
Kebumen 1
Lappeenranta 1
Lauterbourg 1
London 1
Lucknow 1
Managua 1
Manchester 1
Manila 1
Montreal 1
Mosier 1
Mumbai 1
Naples 1
Needham 1
North Bergen 1
Nuremberg 1
Padua 1
Palm Bay 1
Paris 1
Pasto 1
Poplar 1
Queens 1
Redondo Beach 1
Riga 1
San Diego 1
San Francisco 1
San Pedro Sula 1
Santiago 1
Stockholm 1
Tallahassee 1
Tampa 1
Tehran 1
The Dalles 1
Tolentino 1
Washington 1
West Sacramento 1
Zhuhai 1
Ürümqi 1
Totale 225
Nome #
Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study) 168
Persistence of circulating CD169+monocytes and HLA-DR downregulation underline the immune response impairment in PASC individuals: the potential contribution of different COVID-19 pandemic waves 135
Clinical and laboratory parameters correlated to HDV undetectability after 48 weeks of bulevirtide 40
Sarilumab Plus Standard of Care Versus Standard of Care for the Treatment of Severe COVID-19: A Phase 3, Randomized, Open-Labeled, Multi-Center Study (ESCAPE Study) 27
Totale 370
Categoria #
all - tutte 2.384
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.384


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202420 0 0 0 8 1 2 1 0 4 0 4 0
2024/202560 2 3 14 6 2 7 4 5 6 4 5 2
2025/2026180 6 7 12 19 18 4 16 18 19 26 24 11
2026/2027110 17 24 39 30 0 0 0 0 0 0 0 0
Totale 370